The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Adult participants ≥19 years of age
Diagnosis of moderate-to-severe plaque psoriasis
Candidate for phototherapy or systemic therapy
Will begin deucravacitinib according to approved product label
Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)